E A Olsen1, M Harries2, A Tosti3, W Bergfeld4, U Blume-Peytavi5, V Callender6, V Chasapi7, O Correia8, G Cotsarelis9, R Dhurat10, N Dlova11, I Doche12, N Enechukwu13, R Grimalt14, S Itami15, M Hordinsky16, K Khobzei17, W-S Lee18, S Malakar19, A Messenger20, A McMichael21, P Mirmirani22, Y Ovcharenko23, S Papanikou7, G M Pinto3, B M Piraccini24, R Pirmez25, P Reygagne26, J Roberts27, L Rudnicka28, D Saceda-Corralo29, J Shapiro30, T Silyuk31, R Sinclair32, R O Soares33, A Souissi34, A Vogt5, K Washenik35, A Zlotogorski36, D Canfield37, S Vano-Galvan29. 1. Duke University Medical Center, Durham, NC, USA. 2. University of Manchester, MAHSC and NIHR Manchester Biomedical Research Centre, Salford Royal NHS Foundation Trust, Salford, UK. 3. University of Miami Miller School of Medicine, Miami, FL, USA. 4. Cleveland Clinic, Cleveland, OH, USA. 5. Charité-Universitaetsmedizin, Berlin, Germany. 6. Callender Dermatology & Cosmetic Center and Howard University College of Medicine, Washington, DC, USA. 7. Andreas Sygros Hospital, Athens, Greece. 8. Centro Dermatologia Epidermis, Porto, Portugal. 9. University of Pennsylvania, Philadelphia, PA, USA. 10. LTM Medical College & Hospital Sion, Mumbai, India. 11. University of KwaZulu Natal, Durban, South Africa. 12. University of Sao Paulo Medical School, Sao Paulo, SP, Brazil. 13. Nnamdi Azikiwe University Awka, Anambra State, Nigeria. 14. Universitat Internacional de Catalunya, Barcelona, Spain. 15. Oita University, Oita, Japan. 16. University of Minnesota Medical School, Minneapolis, MN, USA. 17. Kyiv Medical University, Kyiv, Ukraine. 18. Yonsei University, Wonju College of Medicine, Wonju, Gangwon-do, Republic of Korea. 19. Rita Skin Foundation, Kolkata, West Bengal, India. 20. Royal Hallamshire Hospital, Sheffield, UK. 21. Wake Forest School of Medicine, Winston Salem, NC, USA. 22. Kaiser Permanente Northern California, Vallejo, CA, USA. 23. V.N. Karazin Kharkiv National University, Kharkiv, Ukraine. 24. University of Bologna, Bologna, Italy. 25. Instituto de Dermatologia Professor Rubem David Azulay - Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, RJ, Brazil. 26. Centre Sabouraud, Hôpital Saint Louis, Paris, France. 27. Northwest Dermatology Institute, Portland, OR, USA. 28. Medical University of Warsaw, Warsaw, Poland. 29. Ramón y Cajal Hospital, IRYCIS, University of Alcala, Madrid, Spain. 30. New York University Grossman School of Medicine, New York, NY, USA. 31. Hair Treatment and Transplantation Center Private Practice, Saint Petersburg, Russia. 32. University of Melbourne and Sinclair Dermatology, Melbourne, VIC, Australia. 33. Cuf Descobertas Hospital, Lisbon, Portugal. 34. Department of Dermatology, University of Tunis El Manar, Tunis, Tunisia. 35. Bosley Medical Group, Beverly Hills, CA and New York University Grossman School of Medicine, New York, NY, USA. 36. Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel. 37. Canfield Scientific, Inc, Parsippany, NJ, USA.
Abstract
BACKGROUND: Frontal fibrosing alopecia (FFA) has become one of the most common causes of cicatricial alopecia worldwide. However, there is a lack of clear aetiology and robust clinical trial evidence for the efficacy and safety of agents currently used for treatment. OBJECTIVES: To enable data to be collected worldwide on FFA using common criteria and assessment methods. METHODS: A multicentre, international group of experts in hair loss was convened by email to create consensus recommendations for clinical trials. Consensus was defined at > 90% agreement on each recommended part of these guidelines. RESULTS: Standardized diagnostic criteria, severity rating, staging, and investigator and patient assessment of scalp hair loss and other clinical features of FFA were created. CONCLUSIONS: These guidelines should allow the collection of reliable aggregate data on FFA and advance efforts in both clinical and basic research to close knowledge gaps in this condition.
BACKGROUND: Frontal fibrosing alopecia (FFA) has become one of the most common causes of cicatricial alopecia worldwide. However, there is a lack of clear aetiology and robust clinical trial evidence for the efficacy and safety of agents currently used for treatment. OBJECTIVES: To enable data to be collected worldwide on FFA using common criteria and assessment methods. METHODS: A multicentre, international group of experts in hair loss was convened by email to create consensus recommendations for clinical trials. Consensus was defined at > 90% agreement on each recommended part of these guidelines. RESULTS: Standardized diagnostic criteria, severity rating, staging, and investigator and patient assessment of scalp hair loss and other clinical features of FFA were created. CONCLUSIONS: These guidelines should allow the collection of reliable aggregate data on FFA and advance efforts in both clinical and basic research to close knowledge gaps in this condition.